CareDx, Inc. CDNA

What this company does

Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a donor-derived cell-free DNA solution for heart transplant patients, and AlloSure Lung, a donor-derived cell-free DNA solution for lung transplant patients. Its headquarters is located in Brisbane, California, and it has other primary operations in Omaha, Nebraska and Stockholm, Sweden. As of December 31, 2025, the company had 765 employees, of which 761 were full-time employees. During 2025, it performed approximately 200,000 commercial tests from its Brisbane, California laboratory. Tests performed on patients covered by Medicare represented 25% of all its tests in 2025. The company is organized and operates as a single reportable segment. The company was originally incorporated in Delaware in December 1998 under the name Hippocratic Engineering, Inc., and changed its name to BioCardia, Inc. in April 1999, to Expression Diagnostics, Inc. in June 2002, to XDx, Inc. in July 2007, and to CareDx, Inc. in March 2014.

Written from the business description in CareDx, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 25 February 2026. Every sentence was checked against that document before publication.